An ongoing dialogue on HIV/AIDS, infectious diseases,
March 1st, 2011
Like It or Not, PrEP Enters the Clinic
Since the publication of iPrEx, the hypothetical decision about whether to prescribe pre-exposure prophylaxis (PrEP) has become a practical reality.
As a result, we’ve posted a case on the Journal Watch/AIDS Clinical Care site, describing someone who requests intermittent pre-exposure prophylaxis to prevent HIV.
It’s a high-risk, HIV-negative man who’s been treated several times with post-exposure prophylaxis. The case was adapted from someone seen recently in our practice, and it raised many questions about what to do in this newly minted area. As there are obviously no “right” answers, we had a broad range of responses within our group. We’ve asked experts in the field to weigh in as well and will publish those responses shortly.
In the meantime, what have you been doing with requests for PrEP? Have you found the “Guidance” (note that these are not yet “Guidelines”) useful? Any helpful or just interesting anecdotes or opinions you wish to share?
One Response to “Like It or Not, PrEP Enters the Clinic”
Paul E. Sax, MD
Associate Editor
NEJM Clinician
Biography | Disclosures & Summaries
Learn more about HIV and ID Observations.
FROM NEJM — Recent Infectious Disease Articles- The End of the War on Biomedical Science? September 19, 2026The turmoil of the past 20 months has inflicted lasting damage on American science and public health. But history and recent events suggest that the attacks will subside.
- Cerebral Schistosomiasis September 19, 2026A rice farmer presented to the ED after a 1-minute episode of arm and leg shaking on the right side. MRI showed linear enhancement associated with a cluster of enhancing nodules and surrounding edema in the left frontal lobe.
- Human Adenovirus B3–Induced Immune Thrombocytopenia and Thrombosis September 17, 2026Virus-induced immune thrombocytopenia and thrombosis after HAdV-B3 infection supports a shared platelet factor 4–targeted immune mechanism linking natural adenovirus infection and adenoviral vector–associated disease.
- Honoring the Legacy of the HIV Epidemic September 17, 2026Progress against the U.S. HIV epidemic is stalling, owing in part to government attacks and fear. But clinicians, patients, and activists can learn from the epidemic’s early heroes and find ways to advance.
- Short or Long Antibiotic Regimens in Orthopedics September 16, 2026In a randomized trial involving adults who received local antibiotics during surgery for orthopedic infection, a short duration of systemic antibiotics was noninferior to a long duration regarding treatment failure at 12 months.
- The End of the War on Biomedical Science? September 19, 2026
Great discussion points on PrEP. GHDonline is partnering with MGH’s HOPE Conference Serires to host a “virtual discussion” on PrEP in practice next week. Would love for you to jump into the conversation and summarize it here on your blog.
http://www.ghdonline.org/hivprevention/discussion/march-7-11-ghdonline-to-host-virtual-panel-discuss/
Panelists from Uganda, South Africa and the United States will add discussions to the online community, highlighting various barriers and opportunities to implementing PrEP in clinical settings; how to encourage long-term adherence; and what additional research questions need to be answered.
All GHDonline members can participate in this virtual discussion. Sign up here if you haven’t already joined and keep your email settings to “per post” to track the discussion live in your inbox.
Panelists:
Douglas Krakower, MD is a fellow in Infectious Diseases at Beth Israel Deaconess Medical Center/Harvard Medical School
Andrew Mujugira, MBChB, MSc is the East Africa regional medical director for the Partners PrEP study.
Vivek Naranbhai, PhD, was involved in CAPRISA microbicide gel study.